Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,585.42
(
-0.40%
)
US TECH 100
23,376.60
(
-0.69%
)
Dow Jones
46,451.69
(
-0.47%
)
Brent Oil
106.89
(
-0.17%
)
Bitcoin
68,300.00
(
-0.81%
)
News Focus
News Focus
Post# of 820624
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

exwannabe

Send PM Follow Ignore
Followers 92
Posts 20563
Boards Moderated 0
Alias Born 09/06/2006

exwannabe

Re: vator post# 630909

Thursday, 09/14/2023 12:29:06 PM

Thursday, September 14, 2023 12:29:06 PM

Post# of 820624

Prior art follows when new patents are filed for changes. Bad argument for you.


BS. By your argument Opdivo and Keytruda have no patent cliff as they have fairly recent patents on the SC formuations.

The SC formulations will help protect their market as the biosimlars will not be able to use SC versions. But the non SC version is off patent once the orrginals expire.

There are very limited ways for patents to get extended. They do not include just filing new patents with extra features.
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent NWBO News
More NWBO News